Aldeyra Therapeutics (NASDAQ:ALDX) Director Buys $98,000.00 in Stock

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Director Richard Douglas purchased 70,000 shares of the stock in a transaction that occurred on Thursday, March 19th. The stock was acquired at an average cost of $1.40 per share, with a total value of $98,000.00. Following the completion of the acquisition, the director directly owned 195,000 shares of the company’s stock, valued at $273,000. This represents a 56.00% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Aldeyra Therapeutics Trading Down 1.1%

ALDX stock opened at $1.81 on Monday. Aldeyra Therapeutics, Inc. has a twelve month low of $1.07 and a twelve month high of $6.81. The company’s 50 day moving average is $4.78 and its two-hundred day moving average is $4.99. The stock has a market cap of $108.93 million, a P/E ratio of -3.18 and a beta of 0.97.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its earnings results on Friday, February 27th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03. On average, equities research analysts predict that Aldeyra Therapeutics, Inc. will post -0.92 earnings per share for the current year.

Key Stories Impacting Aldeyra Therapeutics

Here are the key news stories impacting Aldeyra Therapeutics this week:

• Positive Sentiment: Insider buying: Director/insider Michael Alfieri increased his stake, purchasing 5,000 shares at ~$1.42 on March 18 — a modest signal of insider conviction that can be viewed as supportive amid the sell-off. SEC Filing: Insider Purchase
• Neutral Sentiment: Broker note status: HC Wainwright reaffirmed a Neutral rating and a $2.00 target while publishing updated model revisions. The Neutral stance limits upside endorsement from that shop but keeps coverage steady. HC Wainwright Reaffirms Neutral Rating
• Negative Sentiment: Analyst cuts: HC Wainwright sharply reduced EPS forecasts across 2026–2030 (Q4 2026 from $0.27 to ($0.02); FY2026 to ($0.44); FY2027 to ($0.27); FY2028–2030 also lowered). The revisions signal weaker expected profitability and push down research-driven valuation support. HC Wainwright Research Note
• Negative Sentiment: Lawsuits / investigations: Multiple law firms (Pomerantz; Levi & Korsinsky and others) have launched securities-fraud probes and class-action recruitment, alleging management misstatements around reproxalap’s efficacy and approval prospects. Litigation risk and potential disclosures raise investor uncertainty. Pomerantz Investigation Notice Levi & Korsinsky Alert
• Negative Sentiment: Market reaction / put buying: Heavy put-option activity and a multi-day slump (reports cite ~67% decline since Tuesday) indicate aggressive bearish positioning and rapid de-risking by traders following the FDA Complete Response Letter for reproxalap. That pressure has driven large volume and volatility. Put Options Flow Benzinga: What’s Going On
• Neutral Sentiment: Short-interest reports in recent feeds show inconsistent/zero values (likely data anomalies); treat reported short metrics cautiously until exchanges refresh official figures. No reliable signal from those entries.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ALDX. BTIG Research reaffirmed a “buy” rating on shares of Aldeyra Therapeutics in a report on Tuesday, March 17th. Wall Street Zen downgraded Aldeyra Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, HC Wainwright reissued a “neutral” rating and issued a $2.00 target price (down from $10.00) on shares of Aldeyra Therapeutics in a research report on Wednesday, March 18th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Aldeyra Therapeutics has an average rating of “Hold” and an average price target of $5.50.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Caption Management LLC raised its holdings in Aldeyra Therapeutics by 110.6% during the second quarter. Caption Management LLC now owns 12,664 shares of the biotechnology company’s stock worth $49,000 after purchasing an additional 132,358 shares in the last quarter. Inspirion Wealth Advisors LLC purchased a new stake in Aldeyra Therapeutics in the 4th quarter valued at approximately $52,000. Global Retirement Partners LLC acquired a new position in Aldeyra Therapeutics during the 4th quarter worth approximately $52,000. BNP Paribas Financial Markets increased its position in Aldeyra Therapeutics by 36.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 10,610 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 2,859 shares during the period. Finally, CIBC Private Wealth Group LLC purchased a new position in shares of Aldeyra Therapeutics during the 3rd quarter worth approximately $55,000. 59.71% of the stock is currently owned by institutional investors and hedge funds.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.